Vous êtes sur la page 1sur 2

NEWS RELEASE

5th April 2016, Hyderabad, India


Aurobindo Pharma receives USFDA Approval for Polymyxin B for Injection
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US
Food & Drug Administration (USFDA) to manufacture and market Polymyxin B for Injection USP, 500,000
units/vial. This product is expected to be launched in Q2 FY16-17.
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product
(RLD) Polymyxin B for Injection USP, 500,000 units/vial of Eurohealth International Sarl.

Polymyxin B for Injection is an Anti-Infective used in the treatment of infections of the urinary tract,
meninges, bloodstream and eye caused by susceptible strains of Pseudomonas aeruginosa. The approved
product has an estimated market size of US$ 7.6 million for the twelve months ending February 2016
according to IMS.
This is the 31st ANDA (including two tentative approvals) to be approved out of Unit IV formulation facility in
Hyderabad, India used for manufacturing general injectable products. Aurobindo now has a total of 252
ANDA approvals (216 Final approvals including 10 from Aurolife Pharma LLC and 36 tentative approvals) from
USFDA.
About Aurobindo Pharma Limited:
Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS,
Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active
pharmaceutical ingredients. The companys manufacturing facilities are approved by several leading
regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA
Brazil. The companys robust product portfolio is spread over 7 major therapeutic/product areas
encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics,
supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150
countries.
For further information, please contact:
Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com
Disclaimer:
This press release contain statements that may constitute forward looking statements including and
without limitation, statements relating to product characteristics and uses, sales potential and target dates
for product launch, implementation of strategic initiatives, and other statements relating to our future
business developments and economic performance. While these forward looking statements represent our
judgment and future expectations concerning the development of our business, a number of risks,
uncertainties and other factors could cause actual developments and results to differ materially from our
expectations. The company undertakes no obligation to publicly revise any forward looking statements to
reflect future events or circumstances and will not be held liable for any use of this information.